Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of nonclinical and clinical data.
David Munro, president of Certara’s software division, said, “We have developed these new tools and services to remove the time-consuming task of converting data to CDISC format manually. Manual efforts are both time-consuming and more error prone, which can slow the drug approval process.”
The FDA now requires that clinical and nonclinical study data for all new drug applications (NDAs), abbreviated NDAs (ANDAs) and biologics license applications (BLAs) be submitted electronically in CDISC format. On Dec. 17, 2017 that requirement will extend to all investigational new drug applications (INDs).
In 2016, there were 160 NDAs and BLAs, 864 ANDAs and 786 INDs submitted to FDA.
Certara’s CDISC PK solution includes software, services and consulting:
Phoenix CDISC Navigator provides a user-friendly interface that seamlessly imports CDISC data into Phoenix, converts CDISC data into an analysis-ready format, and then exports CDISC formatted PK parameters. It is ideal for current users who perform PK non-compartmental analysis (NCA) in Phoenix WinNonlin.
Phoenix CDISC Workflow Templates are available for Phoenix users who require automated preparation of NCA Standard Data Tabulation Model (SDTM) clinical and Standard Exchange of Non-Clinical Data (SEND) nonclinical data sets in CDISC-ready formats.
Certara Strategic Consulting is the largest provider of expert PK and PK/pharmacodynamic modeling services and can provide datasets in CDISC-compliant format.
